trial
as of 2026-07-01Accelerated Neuromodulation Therapy for Negative Symptoms of Schizophrenia
NCTId NCT07428460
at a glance
— · Recruiting
Enrollment 75 (estimated)
Sponsored by Douglas Mental Health University Institute
Primary completion 2027-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Recruiting
Enrollment
75 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2026-02-01
Primary completion
2027-12
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Douglas Mental Health University InstituteLead Sponsor
Centre de recherche CERVOCollaborator
Magnus MedicalCollaborator
Investigators
4
David Benrimoh, MD.CM., MSc., MSc., FRCPCPrincipal Investigator
Olivier Roy, MDPrincipal Investigator
Stéphane Potvin, PhDPrincipal Investigator
Lena Palaniyappan, MD, PhDPrincipal Investigator
Sites
3 total
Montreal, CanadaQuébec, CanadaVerdun, Canada
Facts & assertions
4 sourced
Enrollment
75
Phase
NA
Primary Completion Date
2027-12
Status
RECRUITING
relationships
The graph out of here
drug
lead_sponsor
collaborator
company
company
indication
indication
investigator